Arrowhead Pharmaceuticals (ARWR) stock is soaring 12.74% in Tuesday's intraday trading, building on the momentum from its pre-market surge following the release of its fiscal 2025 second quarter financial results that substantially exceeded analyst expectations.
The biotechnology company reported earnings per share of $2.75, a remarkable turnaround from a loss of $1.02 per share in the same quarter last year, and far surpassing the mean analyst expectation of a $0.20 loss per share. Arrowhead's revenue for the quarter ended March 31, 2025, reached an impressive $543 million, dramatically outperforming analyst projections of $29.91 million.
During the earnings call, CEO Dr. Chris Anzalone highlighted the company's strong financial position and its readiness for its first commercial launch anticipated this year, pending regulatory approval for plozasiran. This financial performance marks a significant milestone for Arrowhead Pharmaceuticals as it transitions from a development-stage to a commercial-stage company. The combination of commercial expansion, a productive discovery engine, and a robust balance sheet positions Arrowhead Pharmaceuticals favorably for future growth, explaining the enthusiastic response from investors in today's trading session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.